Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(43,238) | $(35,963) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 176 | 223 |
| Amortization of intangible assets | 333 | 333 |
| Stock-based compensation | 6,885 | 10,870 |
| Non-cash lease expense | 625 | 556 |
| Write-off of deferred issuance costs | 281 | — |
Document
FAQ
- What is Pulse Biosciences, Inc.'s D&A?
- Pulse Biosciences, Inc. (PLSE) reported D&A of $88K in Q2 2026.
- How has Pulse Biosciences, Inc.'s D&A changed year-over-year?
- Pulse Biosciences, Inc.'s D&A decreased by 12.0% year-over-year, from $100K to $88K.
- What is the long-term trend for Pulse Biosciences, Inc.'s D&A?
- Over 4 years (2021 to 2025), Pulse Biosciences, Inc.'s D&A has grown at a -2.0% compound annual growth rate (CAGR), from $444K to $410K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Pulse Biosciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude